Patent US4263286A successfully refreshed from Google Patents.
US4263286A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Therapeutic agent for consciousness disorder and perception and movement disorder
Assignee: Azwell Inc
•
Filing: 1980-05-05
•
Granted: 1981-04-21
•
Expires: 2000-05-05
Abstract
Abstract A therapeutic agent for treating consciousness disorder and perception and movement which comprises as an essential active ingredient a phosphatidic acid derivative selected from a phosphatidylcholine, a phosphatidic acid and a phosphatidylethanolamine in admixture with a conventional carrier. Said agent is administered to the patient suffered from consciousness disorder and perception and movement disorder, particularly the post-traumatic syndrome of the head injury and the sequelae of apoplexy or whiplash injury in oral or parenteral route, preferably in an intravenous route.
Inventors
- 👤 Tadashi Nakajima
- 👤 Kyoji Rikimi
- 👤 Yasuji Soda
- 👤 Kenichi Kashima
- 👤 Akira Miyamoto
- 👤 Yoshikazu Soejima
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 01:46
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/66; A61K31/683; A61K31/685; A61P; A61P25/00; A61P25/02; A61P25/28
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
96 words
A method for treating consciousness disorder and perception and movement disorder which comprises treating a person suffering from said disorders by administering a therapeutically effective amount of a phosphatidylcholine of the formula: ##STR4## wherein R 1 and R 2 are the same or different and are each hydrogen, a residue of a saturated fatty acid having 6 to 22 carbon atoms, or residue of an unsaturated fatty acid having 14 to 20 carbon atoms, provided that at least one of R 1 and R 2 is a residue of the said saturated or unsaturated fatty acid.
Claim 2
Independent Claim
96 words
A method for treating consciousness disorder and perception and movement disorder which comprises treating a person suffering from said disorders by administering a therapeutically effective amount of a phosphatidylcholine of the formula: ##STR4## wherein R 1 and R 2 are the same or different and are each hydrogen, a residue of a saturated fatty acid having 6 to 22 carbon atoms, or residue of an unsaturated fatty acid having 14 to 20 carbon atoms, provided that at least one of R 1 and R 2 is a residue of the said saturated or unsaturated fatty acid.
Claim 3
Dependent Claim
40 words
A method according to claim 1, wherein the phosphatidylcholine is a compound of the formula [I] wherein at least one of R 1 and R 2 is a residue of an unsaturated fatty acid having 14 to 20 carbon atoms.
Claim 4
Dependent Claim
38 words
A method according to claim 1, wherein the phosphatidylcholine is a compound of the formula [I] wherein both of R 1 and R 2 are a residue of an unsaturated fatty acid having 14 to 20 carbon atoms.
Claim 5
Dependent Claim
27 words
A method according to claim 2, wherein the residue of an unsaturated fatty acid is a member selected from the group consisting of linoleoyl, linolenoyl and arachidonyl.
Claim 6
Dependent Claim
27 words
A method according to claim 3, wherein the residue of an unsaturated fatty acid is a member selected from the group consisting of linoleoyl, linolenoyl and arachidonyl.
Claim 7
Dependent Claim
32 words
A method according to claim 1, wherein the phosphatidylcholine is a member selected from the group consisting of soy bean phosphatidylcholine, yolk phosphatidylcholine, soy bean lysophosphatidylcholine, 1,2-dihexanoylphosphatidylcholine, 1-palmitoyl-2-linoleoylphosphatidylcholine, 1-linoleoyl-2-palmitoylphosphatidylcholine, 1,2-dilinoleoylphosphatidylcholine, and 1,2-diarachidonylphosphatidylcholine.
Claim 8
Dependent Claim
27 words
A method according to claim 6, wherein the phosphatidylcholine is a member selected from the group consisting of soy bean phosphatidylcholine, soy bean lysophosphatidylcholine, 1,2-dihexanoylphosphatidylcholine, and 1,2-dilinoleoylphosphatidylcholine.
Claim 9
Dependent Claim
13 words
A method according to claim 7, wherein the phosphatidylcholine is soy bean phosphatidylcholine.
Claim 10
Dependent Claim
25 words
A method according to claim 1, wherein the phosphatidylcholine is administered by a parenteral route in a dose of 1 to 1,500 mg per day.
Claim 11
Dependent Claim
25 words
A method according to claim 1, wherein the phosphatidylcholine is administered by oral route in a dose of 10 mg to 15 g per day.
Claim 12
Dependent Claim
37 words
A method for treating consciousness disorder and perception and movement disorder, which comprises parenterally administering the phosphatidylcholine of claim 9 to a patient suffering from the disease in a dose of 1 to 1,500 mg per day.
Claim 13
Dependent Claim
15 words
A method according to claim 11, wherein the agent is administered in an intravenous route.
References Cited (Backward Citations)
US3772360A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-04-20 | 1984-10-20 | 1985-04-21 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-04-20 | 1988-10-20 | 1989-04-21 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-04-20 | 1992-10-20 | 1993-04-21 | $7700.00 | Window Closed / Lapsed |